⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CCCC News
C4 Therapeutics, Inc.
C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC
Form 8-K
sec.gov
CCCC
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population
globenewswire.com
CCCC
C4 Therapeutics to Participate in Upcoming Conferences
globenewswire.com
CCCC
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
CCCC
Form 8-K
sec.gov
CCCC